Edwards Lifesciences (EW) PT Lowered to $200 at Raymond James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Edwards Lifesciences (EW) PT Raised to $200 at Stifel
April 24, 2019 8:36 AM EDTStifel analyst Rick Wise raised the price target on Edwards Lifesciences (NYSE: EW) to $200.00 (from $190.00) while maintaining a Buy rating.
Overall Solid Start to 2019 Despite Underwhelming 1Q19 TAVR Growth... MoreEdwards Lifesciences (EW) PT Raised to $184 at Deutsche Bank
April 24, 2019 7:14 AM EDTDeutsche Bank raised its price target on Edwards Lifesciences (NYSE: EW) to $184.00 (from $164.00) while maintaining a Hold rating.
... MoreEdwards Lifesciences (EW) PT Raised to $186 at RBC Capital
April 24, 2019 6:39 AM EDTRBC Capital analyst Brandon Henry raised the price target on Edwards Lifesciences (NYSE: EW) to $186.00 (from $182.00) while maintaining a Outperform rating following results.
... MoreEdwards Lifesciences (EW) Tops Q1 EPS by 10c; Raises Outlook
April 23, 2019 4:16 PM EDTEdwards Lifesciences (NYSE: EW) reported Q1 EPS of $1.32, $0.10 better than the analyst estimate of $1.22. Revenue for the quarter came in at $993 million versus the consensus estimate of $989.61 million.
GUIDANCE:
Edwards Lifesciences sees FY2019 EPS of $5.10-$5.35, from $5.05 to $5.30 and versus... More
